In 1990, a breast cancer susceptibility gene designated BRCA1 was localized to chromosome 17q. Mutations within this gene are believed to account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2 (breast cancer 2, early onset), located on chromosome 13q13.1, also confers a high incidence of breast cancer but, unlike BRCA1, does not confer a substantially elevated risk of ovarian cancer. Both BRCA1 and BRCA2 play a role in the maintainance of genome stability, particularly in the homologous recombination pathway for double-strand DNA repair. BRCA2 is regarded as a tumor suppressor gene; tumors with BRCA2 mutations exhibit loss of heterozygosity (LOH) of the wildtype allele. The protein encoded by the BRCA2 gene contains multiple copies of a 70 amino acid motif called the BRC motif. These motifs effect binding to the Rad51 recombinase, which operates in DNA repair.

Applications

IHC-P

Contrôle positif

A431 or HeLa cells. Human breast, thymus, lung, ovary or spleen.

Recommander des dilutions

IHC: 1-2 µg/ml

Reactivité

Human

Immunogène

Recombinant fragment (around Amino Acids 200-500) of human BRCA2 protein. The exact sequence is proprietary.

Hôte

Mouse

Clonalité

Monoclonal

Clone

BRCA2/2158

Isotype

IgG1

Chaînes légères

kappa

Conjuguer

Unconjugated

Purification

Protein A/G chromatography.

Concentration

200 µg/ml

Masse moléculaire

390 kDa

Forme du produit

Liquid

Formulation

Supplied in 10mM Phosphate Buffered Saline with 0.05% BSA and 0.05% Sodium Azide.

Stockage

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Synonymes

BRCA 2, BRCA1/BRCA2 containing complex subunit 2, BRCA2, DNA repair associated, BRCA2_HUMAN, BRCC 2, BRCC2, Breast and ovarian cancer susceptibility gene early onset, breast and ovarian cancer susceptibility protein 2, Breast cancer 2 early onset, Breast Cancer 2 tumor suppressor, Breast cancer susceptibility protein BRCA2, Breast cancer type 2 susceptibility protein, BROVCA2, FACD, FAD, FAD 1, FAD1, FANCB, FANCD, FANCD 1, FANCD1, FANCD1 gene, Fanconi anemia complementation group D1, Fanconi anemia group D1 protein, GLM3, mutant BRCA2, OTTHUMP00000018803, OTTHUMP00000042401, PNCA2, XRCC11

Contrôles isotype

Anticorps secondaires appropriés

Avertissement

Ce produit est uniquement destiné à la recherche. Il n'est pas destiné à un usage diagnostique ou thérapeutique.